Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
European Spatial Biology Center, or ESBC, was launched in Leuven, Belgium in 2022 as a spatial biology services center focused on large-scale spatial transcriptomic and proteomic analysis for academic, biotech, and pharmaceutical customers. The organization works with KU Leuven and VIB and was positioned as the first advanced spatial biology services center of its kind in Europe. In 2023, the business stated that it was formerly known as European Spatial Biology Center and now operates as OMAPiX, offering end-to-end spatial omics services, including scientific consulting, panel design, sample processing, and data analysis. Its services are used to study tissue architecture, cell-cell interactions, biomarkers, and therapeutic targets to support translational research, clinical studies, and drug development. The company appears to be a commercial life sciences tools/services provider rather than a therapeutic drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on European Spatial Biology Center.